AIM ImmunoTech Reports Q1 2025 Financial Results

Aim Immunotech Inc. ( (AIMI) ) has released its Q1 earnings. Here is a breakdown of the information Aim Immunotech Inc. presented to its investors.

AIM ImmunoTech Inc., an immuno-pharma company based in Ocala, Florida, focuses on developing therapeutics for cancers, viral diseases, and immune-deficiency disorders. In its latest earnings report for the first quarter of 2025, AIM ImmunoTech reported a net loss of $3.7 million, an improvement from the $5.8 million loss in the same period last year. The company’s revenue decreased to $16,000 from $40,000, while research and development expenses were significantly reduced to $1.08 million from $1.95 million. AIM’s strategic focus remains on advancing clinical trials for its flagship product, Ampligen, across various therapeutic areas, including pancreatic cancer and chronic fatigue syndrome. Despite financial challenges, including a stockholders’ deficit and a recent delisting from the NYSE American, AIM continues to pursue its research and development goals. Looking ahead, AIM’s management remains committed to regaining compliance with listing standards and advancing its clinical programs to potentially bring new therapies to market.